Hims & Hers reported full-year 2025 revenue of $2.35 billion, up from $1.5 billion in 2024, with 2.5 million subscribers and roughly flat net income of $128 million, and projected 2026 revenue between $2.7 and $2.9 billion, per STAT News, February 23, 2026. The earnings call doubled as a defense of the company's weight-loss business amid federal scrutiny of compounded GLP-1 drugs.
This site publishes information, not medical or financial advice; nothing here is a view on the company's stock. The numbers matter to readers because they show how much of the wellness market now runs through telehealth subscriptions.
What did the CEO say about compounded GLP-1s?
CEO Andrew Dudum told analysts there is a "really durable weight business" even in a scenario where compounded GLP-1s are not available, per STAT News, February 23, 2026. That framing matters because the FDA announced on February 6, 2026 that it intends to restrict GLP-1 ingredients used in non-approved compounded drugs — the category that powered much of the company's recent growth.
The earnings figures show the stakes. Revenue grew more than 50 percent year over year while net income stayed nearly flat, suggesting heavy spending on customer acquisition, per STAT News, 2026. Personalized supplements, skin care, and other daily-use categories remain the subscription base beneath the weight-loss headlines.
Why should wellness readers care about one company's earnings?
Hims & Hers is a bellwether for how consumers buy everyday health products. When a telehealth platform adds millions of subscribers in two years, it reshapes where people get supplements, sleep aids, and weight-loss care — often without a primary-care visit, per STAT News, 2026. Regulatory pressure on one category, like compounded GLP-1s, can redirect millions of customers toward other products on the same apps.
What this changes for readers
If you buy wellness products through telehealth subscriptions, expect the menu to keep shifting with the rules. Compounded GLP-1 offers may be replaced with branded, FDA-approved drugs at higher prices, per the FDA's February 6, 2026 announcement. Before auto-renewing any plan, check what exactly you are getting — an FDA-approved medicine or a compounded copy — and whether your clinician agrees it suits you.
The bottom line
Hims & Hers closed 2025 with $2.35 billion in revenue, 2.5 million subscribers, and 2026 guidance of $2.7–2.9 billion, per STAT News, February 23, 2026, even as its flagship weight-loss category faces an FDA crackdown on compounded GLP-1s. Watch how the company's offering mix changes; that is the signal for where telehealth wellness goes next.
